ReviewAdvances in experimental medicine and biology2025
Epigenetic Regulation in Drosophila Tumor Models.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This chapter investigates the role of epigenetic regulation in tumorigenesis using Drosophila melanogaster as a model organism. It underscores the advantages of Drosophila for studying epigenetic mechanisms in cancer and focuses on key epigenetic regulators, such as Polycomb and Trithorax complexes, which modulate chromatin structure and gene expression. The chapter explores the roles of these complexes in various Drosophila tissues, including imaginal discs, the central nervous system, and adult stem cells, emphasizing their context-dependent functions in both tumor suppression and promotion. It challenges the somatic mutation theory (SMT) of cancer by emphasizing theories and experimental results suggesting a major contribution of epigenetic mechanisms in cancer initiation and progression. The concept of tumor reversion through epigenetic reprogramming is introduced, suggesting that non-mutational changes can revert tumor cells to a benign state. The tissue organization field theory (TOFT) and the epigenetic progenitor hypothesis are discussed to explain the epigenetic origins of cancer. Significant data highlight the critical role of epigenetic regulation in maintaining cellular identity, preventing tumorigenesis, and contributing to cancer when dysregulated. The chapter discusses the potential for epigenetic therapies and the need for further research to unravel the complex interplay between genetic and epigenetic factors in cancer.
Indexed as
Identifiers
40745141What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.